AIM ImmunoTech (AIM ImmunoTech) Cash-to-Debt : 18.20 (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is AIM ImmunoTech Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. AIM ImmunoTech's cash to debt ratio for the quarter that ended in Dec. 2023 was 18.20.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, AIM ImmunoTech could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for AIM ImmunoTech's Cash-to-Debt or its related term are showing as below:

AIM' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.31 Med: 29.53 Max: No Debt
Current: 18.2

During the past 13 years, AIM ImmunoTech's highest Cash to Debt Ratio was No Debt. The lowest was 0.31. And the median was 29.53.

AIM's Cash-to-Debt is ranked better than
63.42% of 1539 companies
in the Biotechnology industry
Industry Median: 6.5 vs AIM: 18.20

AIM ImmunoTech Cash-to-Debt Historical Data

The historical data trend for AIM ImmunoTech's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

AIM ImmunoTech Cash-to-Debt Chart

AIM ImmunoTech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

1.38

17.07

323.95

40.85

18.20

AIM ImmunoTech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															40.85	37.90	35.37	29.91	18.20

Competitive Comparison of AIM ImmunoTech's Cash-to-Debt

For the Biotechnology subindustry, AIM ImmunoTech's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AIM ImmunoTech's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where AIM ImmunoTech's Cash-to-Debt falls into.

AIM ImmunoTech Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

AIM ImmunoTech's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	13.07	/	(0.223	+	0.495)
	=	18.20

AIM ImmunoTech's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	13.07	/	(0.223	+	0.495)
	=	18.20

AIM ImmunoTech (AMEX:AIM) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

AIM ImmunoTech Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of AIM ImmunoTech's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

AIM ImmunoTech (AIM ImmunoTech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (AMEX:AIM) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

HXB2:Germany

Address

2117 SW Highway 484, Ocala, FL, USA, 34473

Website

https://www.aimimmuno.com

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

Executives

Thomas K. Equels	director, officer: Vice Chairman of Board	2117 SOUTHWEST HIGHWAY 484, OCALA FL 34473
Nancy Bryan	director	550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Stewart Appelrouth	director	2117 SW HIGHWAY 484, OCALA FL 34473
Rodino Peter W. Iii	director	2117 SOUTHWEST HIGHWAY 484, OCALA FL 34473
Ellen M Lintal	officer: CFO	2117 SW HWY 484, OCALA FL 34473
William M Mitchell	director	2117 SW HWY 484, OCALA FL 34473
Wayne S. Springate	officer: VP of Operations	600 MAIN STREET, SUITE 2, RIVERTON NJ 08077
David R Strayer	other: Medical Director	600 MAIN STREET, SUITE 2, RIVERTON NJ 08077
Adam Pascale	officer: CFO	600 MAIN STREET, SUITE 2, RIVERTON NJ 08077
Ralph Christopher Cavalli	officer: VP, Quality Control	510 MURDOCH ROAD, PHILADELPHIA PA 19119
Russel J Lander	officer: VP of Process/QualityAssurance	784 BAEDER ROAD, JENKINTOWN PA 19046
Robert Iv Dickey	officer: Senior Vice President	320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Bernhardt Charles Thomas Iii	officer: CFO	23 BIRCH ROAD, MALVERN PA 19355
Steven D Spence	director	250 EAST 54TH STREET APARTMENT 36C, NEW YORK NY 10022
Anthony Bonelli	officer: President & COO	P.O. BOX 521, NEW VERNON NJ 07976